1. Vaccines and Vaccination in Historical Perspective
2. Developing Vaccines in the Era of Reverse Vaccinology
3. Initial Clinical Evaluation of New Vaccine Candidates
4. Special Issues in Performing Vaccine Trials in Developing Countries
5. Long-Term Evaluation of Vaccine Performance: Methodological
6. Ethical Considerations in the Conduct of Vaccine Trials in Developing Countries
7. Vaccine Economics: Assuring That Vaccines Are Developed for and Available in Developing Countries
8. Development and Supply of Vaccines: An Industry Perspective
9. Reaching Every Child: Achieving Equity in Global Immunization
10. A Paradigm for International Cooperation: The GAVI Alliance
11. Economic Analyses of Vaccines and Vaccination Programs
12. An Overview of U.S. Food and Drug Administration Licensure of Vaccines
13. Assuring Vaccine Quality by Strengthening Regulatory Agencies:The Work of the World Health Organization
14. Vaccine Safety
15. Manufacturing of Vaccines
16. Polio Eradication: Ongoing Innovation to End an Ancient Scourge
17. Recent Advances in Immunology That Impact Vaccine Development
18. Modulating Vaccine Responses with Innate Immunity
19. Immunodominance, Deceptive Imprinting, and Immune Refocusing Technology
20. Standardization and High-Throughput Measurement of T-Cell Responses to Vaccines
21. Transition to High-Throughput Laboratory
Assays to Evaluate Multivalent Vaccines 22. The Challenge of Vaccine Protection in Very Young Infants
23. The Challenge of Inducing Vaccine Protection in the Elderly
24. Vaccination and Autoimmunity
25. Adjuvants for the Future
26. TLR9 Agonists for Immune Enhancement of Vaccines
27. Use of Genetically or Chemically Detoxified Mutants of Cholera and Escherichia coli Heat-Labile Enterotoxins as Mucosal Adjuvants
28. Recent Developments in Nonliving Antigen Delivery Systems
29. Virus-Like Particles as Vaccines and Vaccine Delivery Systems
30. Subunit Vaccines Produced Using Plant Biotechnology
31. Lipopeptide-Based Vaccines
32. Vaccines Based on Dendritic Cell Biology 33. Vaccinia Virus and Other Poxviruses as Live Vectors
34. Replication-Defective and Competent Adenovirus Recombinants as Vaccine Vectors
35. RNA Virus Replicon Vaccines
36. Engineering of Attenuated Salmonella enterica Serovars for Use as Live Vector Vaccines
37. DNA Vaccines
38. Overview of Heterologous Prime-Boost Immunization Strategies
39. Mucosal Immunization and Needle-Free Injection Devices
40. Advances in Transcutaneous Vaccine Delivery
41. Rationalizing Childhood Immunization Programs: The Variation in Schedules and Use of Combination Vaccines
42. Meningococcal Conjugate and Protein-Based Vaccines
43. Post-Licensure Impact of Haemophilus influenzae Type b and Serogroup C Neisseria meningitidis Conjugate Vaccines in Industrialized Countries
44. Haemophilus influenzae Type b Disease Burden and the Impact of Programmatic Infant Immunization in Developing Countries
45. Pneumococcal Protein-Polysaccharide Conjugate Vaccines
46. Pneumococcal Common Proteins and Other Vaccine Strategies
47. Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis, and Escherichia coli O157:H7
48. Attenuated Strains of Salmonella enterica Serovars Typhi and Paratyphi as Live Oral Vaccines Against Enteric Fever
49. Oral Cholera Vaccines
50. Novel Vaccines Against Tuberculosis
51. Influenza
52. Chimeric Vaccines Against Japanese
Encephalitis, Dengue,and West Nile
53. Vaccines Against Rotavirus Gastroenteritis
54. Novel Strategies for Immunizing Infants in Developing Countries
Who Are Too Young to Receive the Currently LicensedMeasles Vaccines
55. Challenges and Prospects for the Development of an HIV Vaccine
56. Vaccine Strategies to Prevent Dengue
57. Vaccination Against the Hepatitis C Virus
58. Vaccines Against Respiratory Syncytial Virus and Parainfluenza Viruses
59. Cytomegalovirus Vaccines
60. Epstein–Barr Virus Vaccines
61. Herpes Simplex Vaccines
62. Development of Vaccines to Prevent Group A Streptococcal Infections and Rheumatic Fever
63. Vaccines Against Group B Streptococcus
64. Overview of Live and Subcellular Vaccine Strategies Against Shigella
65. Vaccines Against Enterotoxigenic Escherichia coli
66. Multivalent Shigella Enterotoxigenic Escherichia coli Vaccine
67. Vaccines for Staphylococcus aureus Infections
68. Chlamydia trachomatis Vaccines
69. Malaria Vaccines in Clinical Development: Introduction and Recombinant/Subunit Approaches
70. Gene-Based Malaria Vaccines
71. Pre-erythrocytic and Asexual Erythrocytic Stage Whole-Organism Malaria Vaccines
72. Vaccines Against Leishmania
73. Vaccines Against Schistosomiasis
74. Vaccines Against Entamoeba histolytica
75. Hookworm Vaccines
76. Improved Smallpox Vaccines
77. Anthrax Vaccines
78. Tularemia Vaccines
79. Vaccines Against Plague
80. Development of Vaccines for Ebola and Marburg Viruses: Efficacy and Regulatory Considerations
81. Therapeutics and Vaccines Against Hendra and Nipah Viruses
82. Vaccines Against Lassa Fever
83. Hantavirus Vaccines
84. SARS Vaccines
85. Cancer-Specific Vaccines
86. Vaccines Against Human Papillomaviruses
87. Vaccines Against Alzheimer’s and Other Neurodegenerative Diseases
88. Vaccination for Autoimmune and Other Chronic Inflammatory Disorders
89. Immunotherapies To Treat Drug Addiction
2. Developing Vaccines in the Era of Reverse Vaccinology
3. Initial Clinical Evaluation of New Vaccine Candidates
4. Special Issues in Performing Vaccine Trials in Developing Countries
5. Long-Term Evaluation of Vaccine Performance: Methodological
6. Ethical Considerations in the Conduct of Vaccine Trials in Developing Countries
7. Vaccine Economics: Assuring That Vaccines Are Developed for and Available in Developing Countries
8. Development and Supply of Vaccines: An Industry Perspective
9. Reaching Every Child: Achieving Equity in Global Immunization
10. A Paradigm for International Cooperation: The GAVI Alliance
11. Economic Analyses of Vaccines and Vaccination Programs
12. An Overview of U.S. Food and Drug Administration Licensure of Vaccines
13. Assuring Vaccine Quality by Strengthening Regulatory Agencies:The Work of the World Health Organization
14. Vaccine Safety
15. Manufacturing of Vaccines
16. Polio Eradication: Ongoing Innovation to End an Ancient Scourge
17. Recent Advances in Immunology That Impact Vaccine Development
18. Modulating Vaccine Responses with Innate Immunity
19. Immunodominance, Deceptive Imprinting, and Immune Refocusing Technology
20. Standardization and High-Throughput Measurement of T-Cell Responses to Vaccines
21. Transition to High-Throughput Laboratory
Assays to Evaluate Multivalent Vaccines 22. The Challenge of Vaccine Protection in Very Young Infants
23. The Challenge of Inducing Vaccine Protection in the Elderly
24. Vaccination and Autoimmunity
25. Adjuvants for the Future
26. TLR9 Agonists for Immune Enhancement of Vaccines
27. Use of Genetically or Chemically Detoxified Mutants of Cholera and Escherichia coli Heat-Labile Enterotoxins as Mucosal Adjuvants
28. Recent Developments in Nonliving Antigen Delivery Systems
29. Virus-Like Particles as Vaccines and Vaccine Delivery Systems
30. Subunit Vaccines Produced Using Plant Biotechnology
31. Lipopeptide-Based Vaccines
32. Vaccines Based on Dendritic Cell Biology 33. Vaccinia Virus and Other Poxviruses as Live Vectors
34. Replication-Defective and Competent Adenovirus Recombinants as Vaccine Vectors
35. RNA Virus Replicon Vaccines
36. Engineering of Attenuated Salmonella enterica Serovars for Use as Live Vector Vaccines
37. DNA Vaccines
38. Overview of Heterologous Prime-Boost Immunization Strategies
39. Mucosal Immunization and Needle-Free Injection Devices
40. Advances in Transcutaneous Vaccine Delivery
41. Rationalizing Childhood Immunization Programs: The Variation in Schedules and Use of Combination Vaccines
42. Meningococcal Conjugate and Protein-Based Vaccines
43. Post-Licensure Impact of Haemophilus influenzae Type b and Serogroup C Neisseria meningitidis Conjugate Vaccines in Industrialized Countries
44. Haemophilus influenzae Type b Disease Burden and the Impact of Programmatic Infant Immunization in Developing Countries
45. Pneumococcal Protein-Polysaccharide Conjugate Vaccines
46. Pneumococcal Common Proteins and Other Vaccine Strategies
47. Polysaccharide-Based Conjugate Vaccines for Enteric Bacterial Infections: Typhoid Fever, Nontyphoidal Salmonellosis, and Escherichia coli O157:H7
48. Attenuated Strains of Salmonella enterica Serovars Typhi and Paratyphi as Live Oral Vaccines Against Enteric Fever
49. Oral Cholera Vaccines
50. Novel Vaccines Against Tuberculosis
51. Influenza
52. Chimeric Vaccines Against Japanese
Encephalitis, Dengue,and West Nile
53. Vaccines Against Rotavirus Gastroenteritis
54. Novel Strategies for Immunizing Infants in Developing Countries
Who Are Too Young to Receive the Currently LicensedMeasles Vaccines
55. Challenges and Prospects for the Development of an HIV Vaccine
56. Vaccine Strategies to Prevent Dengue
57. Vaccination Against the Hepatitis C Virus
58. Vaccines Against Respiratory Syncytial Virus and Parainfluenza Viruses
59. Cytomegalovirus Vaccines
60. Epstein–Barr Virus Vaccines
61. Herpes Simplex Vaccines
62. Development of Vaccines to Prevent Group A Streptococcal Infections and Rheumatic Fever
63. Vaccines Against Group B Streptococcus
64. Overview of Live and Subcellular Vaccine Strategies Against Shigella
65. Vaccines Against Enterotoxigenic Escherichia coli
66. Multivalent Shigella Enterotoxigenic Escherichia coli Vaccine
67. Vaccines for Staphylococcus aureus Infections
68. Chlamydia trachomatis Vaccines
69. Malaria Vaccines in Clinical Development: Introduction and Recombinant/Subunit Approaches
70. Gene-Based Malaria Vaccines
71. Pre-erythrocytic and Asexual Erythrocytic Stage Whole-Organism Malaria Vaccines
72. Vaccines Against Leishmania
73. Vaccines Against Schistosomiasis
74. Vaccines Against Entamoeba histolytica
75. Hookworm Vaccines
76. Improved Smallpox Vaccines
77. Anthrax Vaccines
78. Tularemia Vaccines
79. Vaccines Against Plague
80. Development of Vaccines for Ebola and Marburg Viruses: Efficacy and Regulatory Considerations
81. Therapeutics and Vaccines Against Hendra and Nipah Viruses
82. Vaccines Against Lassa Fever
83. Hantavirus Vaccines
84. SARS Vaccines
85. Cancer-Specific Vaccines
86. Vaccines Against Human Papillomaviruses
87. Vaccines Against Alzheimer’s and Other Neurodegenerative Diseases
88. Vaccination for Autoimmune and Other Chronic Inflammatory Disorders
89. Immunotherapies To Treat Drug Addiction
Myron M. Levine is Director of the Center for Vaccine Development, Professor of Medicine, and Head of the Division of Geographic Medicine, as well as Professor of Pediatrics and Head of the Division of Infectious Diseases and Tropical Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Doody's Review Service
"This comprehensive book on vaccines will serve as a reference for all those with an interest in the field."
Clinical Infectious Diseases (for the Third Edition)
"…This excellent book can be considered a standard text in the field of vaccinology."
The New England Journal of Medicine (for the Third Edition)
"…a valuable book for those who would like an overview of vaccines in the pipeline….it contains a lot of up-to-date information for those interested in future trends of infectious-disease prevention."
